Publications

Browse Publications:

By Category:

• Research Papers (111)
• Abstract Posters (2)
• Presentations (6)

By Physician:

• David Charytan, MD (3)
• Alanna Coolong, MD (2)
• Donald E. Cutlip, MD (52)
• Ralph D'Agostino, PhD (2)
• Elazer R. Edelman, MD, PhD (0)
• Maurizio Fava, MD (0)
• Lawrence Garcia, MD (0)
• Ernest V. Gervino, Sc.D., FACSM (1)
• Michael Gibson, MD (2)
• Kalon K.L. Ho, MD, MSc (21)
• Michael Jaff, MD (0)
• Mark Josephson, MD (4)
• Joseph Massaro, PhD (5)
• Laura Mauri, MD (23)
• Andrew Nierenberg, MD (0)
• Mark H. Pollack, MD (1)
• Jeffrey J. Popma, MD (40)
• Matthew R. Reynolds, M.D, M.Sc. (9)
• Alexei Shvilkin, MD, PhD (0)
• Peter Zimetbaum, MD (20)

Publications From: Laura Mauri, MD

Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol. 2002 Nov 15;90(10):1079-83.

Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation. 2008 Feb 12;117(6):790-7.

Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007 Mar 8;356(10):1020-9.

The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. J Am Coll Cardiol. 2007 Oct 9;50(15):1442-9.

The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. Curr Opin Cardiol. 2007 Nov;22(6):565-571.

Devices for Distal Protection During Percutaneous Coronary Revascularization. Circulation 2006; 113;2651-2656

Drug-Eluting Stenting for Unprotected Left Main Coronary Artery Disease. JACC February 21, 2006:878-81.

Surrogates, Substudies, and Real Clinical End Points in Trials of Drug-Eluting Stents. JACC April 19, 2005:1206-12.

Carotid artery stenting with emboli protection surveillance study: thirty-day results of the CASES-PMS study. Catheter Cardiovasc Interv. 2007 Aug 1;70(2):316-23.

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.

Impact of Late Incomplete Stent Apposition After Sirolimus-Eluting Stent Implantation on 4-Year Clinical Events. Intravascular Ultrasound Analysis from the Multicenter, Randomized, RAVEL, E-SIRIUS and SIRIUS Trials.Heart. 2007 Aug 29; [Epub ahead of print]

Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006 Dec 19;48(12):2440-7.

Long-Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts

Late Loss Versus Target Lesion Revascularization: What Is the Difference in the Numbers?

The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J. 2006 Sep;152(3):558-64.

Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped? Curr Cardiol Rep. 2006 Jul;8(4):267-71.

Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation. 2005 Nov 1;112(18):2833-9.

Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison.Circulation. 2005 Jun 28;111(25):3435-42.

Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2005 May 15;95(10):1140-5.

Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007 Oct 2;50(14):1299-304.

Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart. 2008 Mar;94(3):322-8.

Studies of Drug-Eluting Stents: To Each His Own? Circulation 2008 Apr 22;117(16):2047-50.

Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. 2008 May 13;51(19):1844-53.

Meet The HCRI Team

Charles Frizzell

Chief of Operations

Since 1997, Charles Frizzell has been responsible for the oversight of day-to-day company operations. He has implemented company-wide…

Submit an RFP

Quick Links

• Contact HCRI
• Careers at HCRI
• Information for Patients

930-W Commonwealth Avenue
Boston MA 02215
t: 617.632.1515    f: 617.632.1580

©2008 Harvard Clinical Research Institute